Product Description

Glycosil® is a thiol-modified hyaluronic acid and a constituent of native extracellular matrix (ECM). Glycosil is used in conjunction with Gelin-S® or ECM proteins such as laminin, collagen, or fibronectin for most 3-D cell culture and tissue-engineering applications. Tested for bacteria and endotoxins. Glycosil hyaluronic acid is a component of the HyStem®, HyStem-C and HyStem-HP hydrogel kits and can be purchased separately in individual vials.

Glycosil® (thiol-modified sodium hyaluronate) is packaged in 5 mL vials containing 50 mg. Vials are blanketed by nitrogen and under a slight vacuum.

Store Glycosil in the original vial, unopened, at -20°C for up to one year. Do not uncap the Glycosil vials since they will crosslink in the presence of oxygen. Use a syringe and needle to add DG Water and remove product from the vials through the septum.

Note: It is recommended to reconstitute each vial in its entirety.

Directions for Use

Glycosil is prepared by dissolving the lyophilized solid in the DG Water (or any sterile, degassed, deionized water). When re-constituted, it will be in 1x phosphate buffered saline (PBS), pH ~7.4. The amount of DG Water used for dissolution will depend on the vial.

Glycosil should be prepared in the following manner:

  1. Allow the Glycosil vial to come to room temperature.
  2. Under aseptic conditions, using a syringe and needle, add 5 mL of DG Water to the Glycosil vial.
  3. Place the vial horizontally on a rocker or shaker. It will take <40 minutes for the solids to fully dissolve. Warming to 37°C and/or gently vortexing will speed up dissolving time. Solutions will be clear and slightly viscous.
  4. Use with Extralink® or Extralink-Lite to form a hydrogel.
  5. Typically, crosslinkers are used in a 1:4 volume ratio with the polymer (i.e. 1.0 mL of Glycosil is crosslinked with 0.25 mL Extralink-Lite; or 0.5 mL Glycosil combined with 0.5 mL Gelin-S® is crosslinked with 0.25 mL Extralink). Note: The gelation time will be shorter for gels not incorporating Gelin-S. Hydrogels made using only Glycosil will not support cell attachment. Use with Gelin-S for cell attachment.

Product Applications

Glycosil reconstituted with the recommended volume of degassed water will be a 1% solution of thiolated HA in 1X PBS salts. Upon reconstitution, Glycosil will remain liquid for several hours until crosslinker (such as Extralink or PEGSSDA) is added, at which point gelation will occur after 20-30 minutes with no temperature or pH manipulation required. Even without crosslinker, a gel will eventually form due to auto-crosslinking. Please use Glycosil within four hours of reconstitution. Diluting Glycosil with phosphate-buffered saline or cell culture media will increase gelation time or ultimately prevent gelation all together. Reconstituting Glycosil in any solvent except pure water will alter the salt balance and may impact gelation kinetics or gel properties.

Product References

References for HyStem®:

Gaetani, R., et al. (2015) Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 61: 339-348. PMID: 17335875.

Prestwich, G.D., et al. (2007) 3-D culture in synthetic extracellular matrices: new tissue models for drug toxicology and cancer drug discovery. Adv Enzyme Regul 47: 196-207. PMID: 17335875.

Shu, X.Z., et al. (2006) Synthesis and evaluation of injectable, in situ crosslinkable synthetic extracellular matrices for tissue engineering. J Biomed Mater Res A 79: 901-912. PMID: 16941590.

Shu, X.Z., et al. (2003) Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials 24: 3825-3834. PMID: 12818555.

S. Cai, et al. (2005) Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.Biomaterials, 26, 6054-6067.

D. B. Pike, et al. (2006) Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials, 27, 5242–5251.

G. D. Prestwich, et al. (2007) 3-D Culture in Synthetic Extracellular Matrices: New Tissue Models for Drug Toxicology and Cancer Drug Discovery. invited, Adv. Enz. Res., in press (2007).

X. Z. Shu, et al, (2006) Synthesis and Evaluation of Injectable, In Situ Crosslinkable Synthetic Extracellular Matrices (sECMs) for Tissue Engineering. J. Biomed Mater. Res. A, 79A(4), 901-912.

Shu, X.Z., et al. (2004) In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 25: 1339-1348. PMID: 14643608. 

Mehra, T.D., et al. (2006) Molecular stenting with a crosslinked hyaluronan derivative inhibits collagen gel contraction. J Invest Dermatol 126: 2202-2209. PMID: 16741511. 

Shu, X.Z., et al. (2004) Attachment and spreading of fibroblasts on an RGD peptide-modified injectable hyaluronan hydrogel. J Biomed Mater Res A 68: 365-375. PMID: 14704979. 

Ghosh, K., et al. (2007) Cell adaptation to a physiologically relevant ECM mimic with different viscoelastic properties. Biomaterials 28: 671-679. PMID: 17049594.

Product Certificate of Analysis

No result for .

Product Disclaimer

This product is for R&D use only and is not intended for human or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.